Daptomycin. Fresh from the Pipeline
Nature Reviews Drug Discovery
In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?
Raja, Aarti; J. LaBonte; J. Lebbos; and P. Kirkpatrick. 2003. "Daptomycin. Fresh from the Pipeline." Nature Reviews Drug Discovery , (). https://nsuworks.nova.edu/cnso_bio_facarticles/70